期刊文献+

解读2015年WHO肺、胸膜、胸腺及心脏肿瘤分类(肺) 被引量:19

下载PDF
导出
摘要 2015年3月,国际癌症研究机构(International Agency for Researchon Cancer,IARC)第4版《WHO肺、胸膜、胸腺和心脏肿瘤分类》(简称新版)正式出版,与2004年第3版(简称旧版)相比,新版与时俱进,肺肿瘤分类并非形态学一家独大,而是博采众长,除了采纳2011年国际肺癌研究协会(International Association for the Study of Lung Cancer,IASLC)、美国胸科学会(AmericanThoracicSociety,ATs)和欧洲呼吸学会(EuropeanRespiratorySociety,ERS)肺腺癌国际多学科分类(International Muhidisciplinary Classification of Lung adenocarcinoma),还收录了该领域其他研究成果,在出版层面开启了WHO精准医学(precision medicine,PM)及多学科团队合作(multidisciplinary team,MDT)的新时代,新版将腺癌排在首位,顶层设计(top-down design),分层管理(stratification management),体现了组织学类型、分子标志物与临床特征之间的新关联,诊断可重复性(reproducibility)与临床一致性(consistency)更强,更有利于临床实践、调查研究及科学试验。本文通过学习与解读,重点介绍新增内容。
出处 《重庆医学》 CAS 北大核心 2017年第1期4-23,共20页 Chongqing medicine
关键词 肺肿瘤 WHO 分类
  • 相关文献

参考文献4

二级参考文献161

  • 1Lord RV, Brabender J, Gandara D, et al: Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8:2286-2291, 2002. 被引量:1
  • 2Rosell R, Danenberg KD, Alberola V, et al: Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 10:1318-132S, 2004. 被引量:1
  • 3Rosell R, Scagliotti G, Danenberg KD, et al Transcripts in pretreatment biopsies from a threearm randomized trial in metastatic non-small-cell lung cancer. Oncogene 22:3548-3553, 2003. 被引量:1
  • 4Simon G, Sharma A, Li X, et al Feasibility and efficacy of molecular analy- sis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol25:2741-2746, 2007. 被引量:1
  • 5Tibaldi C, Giovannetti E, Vasile E, et al: Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatintreated advanced non-small cell lung cancer patients. Clin Cancer Res 14:1797-1803, 2008. 被引量:1
  • 6Dowlati A, Gray R, Sandier AB, et al: Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab: An Eastern Cooperative Oncology Group Study. Clin Cancer Res 14:1407-1412, 2008. 被引量:1
  • 7Dudek AZ, Mahaseth H: Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: Correlation with treatment response and survival. Cancer Invest 23:193-200, 2005. 被引量:1
  • 8Lissoni P, Rovelli F, Malugani F, et al: Changes in circulating VEGF levels in relation to clinical response during chemotherapy for metastatic cancer. IntJ Biol Markers 18:152-155, 2003. 被引量:1
  • 9Mihaylova Z, Ludovini V, Gregorg V, et al Serum level changes of matrix metalloproteinases 2 and 9, vascular endothelial growth factor and epidermal growth factor receptor during platinum-based chemotherapy in advanced non-small cell lung cancer patients. J BUON 12:105-111, 2007. 被引量:1
  • 10Tas F, Duranyildiz D, Oguz H, et al: Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer. Cancer Invest 24:576-580, 2006. 被引量:1

共引文献804

同被引文献68

引证文献19

二级引证文献49

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部